Integrating RAS status into prognostic signatures for adenocarcinomas of the lung

• Published in: Clinical cancer research Vol. 21; no. 6; pp. 1477 - 1486
• Main Authors: Starmans, Maud H W, Pintilie, Melania, Chan-Seng-Yue, Michelle, Moon, Nathalie C, Haider, Syed, Nguyen, Francis, Lau, Suzanne K, Liu, Ni, Kasprzyk, Arek, Wouters, Bradly G, Der, Sandy D, Shepherd, Frances A, Jurisica, Igor, Penn, Linda Z, Tsao, Ming-Sound, Lambin, Philippe, Boutros, Paul C
• Format: Journal Article
• Language: English
• Published: United States 15.03.2015
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - mortality; Adenocarcinoma of Lung; Enzyme Activation - genetics; Gene Expression Profiling; Humans; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Models, Theoretical; Mutation - genetics; Prognosis; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; Proto-Oncogene Proteins p21(ras); ras Proteins - genetics; ras Proteins - metabolism

While the dysregulation of specific pathways in cancer influences both treatment response and outcome, few current prognostic markers explicitly consider differential pathway activation. Here we explore this concept, focusing on K-Ras mutations in lung adenocarcinoma (present in 25%-35% of patients)...